Prospective Grant of Exclusive Evaluation License: Development of Antibody-Drug Conjugates Comprising Topoisomerase Inhibitors for the Treatment of Human Cancers, 54987 [2014-21855]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 178 / Monday, September 15, 2014 / Notices
MedicalDevicesAdvisoryCommittee/
CirculatorySystemDevicesPanel/
ucm342357.htm.
Dated: September 9, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–21815 Filed 9–12–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
Evaluation License: Development of
Antibody-Drug Conjugates Comprising
Topoisomerase Inhibitors for the
Treatment of Human Cancers
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to practice the
inventions embodied in U.S. Provisional
Patent Application No. 60/844,027
entitled, ‘‘Azonafide derived tumor and
cancer targeting compounds,’’ filed
September 12, 2006 [HHS Ref. No. E–
160–2006/0–US–01], PCT Application
No. PCT/US2007/078233 entitled,
‘‘Azonafide derived tumor and cancer
targeting compounds,’’ filed September
12, 2007 [HHS Ref. No. E–160–2006/0–
PCT–02], European Patent Application
No. 7842310.0 entitled, ‘‘Azonafide
derived tumor and cancer targeting
compounds,’’ filed September 12, 2007
[HHS Ref. No. E–160–2006/0–EP–03],
and U.S. Patent Application No. 12/
441,029 entitled, ‘‘Azonafide derived
tumor and cancer targeting
compounds,’’ filed March 12, 2009 now
US Patent No. 8,008,316 issued August
30, 2011 [HHS Ref. No. E–160–2006/0–
US–04], and all related continuing and
foreign patents/patent applications for
the technology family, to Oncolinx, Inc.
The patent rights in these inventions
have been assigned to the Government
of the United States of America.
The prospective exclusive evaluation
option license territory may be
worldwide and the field of use may be
limited to the development and use of
the licensed patent rights as a
component of an antibody-drug
conjugate for the treatment of human
cancers. Upon expiration or termination
of the exclusive evaluation option
license, Oncolinx will have the right to
execute an exclusive patent
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:10 Sep 12, 2014
Jkt 232001
commercialization license which will
supersede and replace the exclusive
evaluation option license with no
broader territory than granted in the
exclusive evaluation option license and
the field of use will be commensurate
with the commercial development plan
at the time of conversion.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
September 30, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries,
comments, and other materials relating
to the contemplated exclusive
evaluation option license should be
directed to: Jennifer Wong, M.S., Senior
Licensing and Patenting Manager, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
4633; Facsimile: (301) 402–0220; Email:
wongje@od.nih.gov.
SUPPLEMENTARY INFORMATION: The
present technology provides compound
formulation and method of use of
improved derivatives of 2-[2′-(2aminoethyl)-2-methyl-ethyl]-l,2dihydro-6-methoxy-3H-dibenz[de,h]isoquinoline-l,3-dione (herein
referred to as azonafides), anthracenebased DNA intercalcators that inhibit
tumor growth. The synthesized
azonafides can be attached to a ligand
or antibody to recognize specific
receptors on cancer cells and delivered
as a targeted cytotoxic payload. The
azonafides have been developed to
allow for easy modification with
different peptide linkers and antibodies,
but also allow for rapid release once
cleaved in lysosomes after delivery to
the cancer cell enabling highly targeted
attack of cancer cells. The azonafides
have reduced toxicity and lower
development of drug resistance.
The prospective exclusive evaluation
option license is being considered under
the small business initiative launched
on October 1, 2011 and will comply
with the terms and conditions of 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive evaluation option
license, and a subsequent exclusive
patent commercialization license, may
be granted unless within fifteen (15)
days from the date of this published
notice, the NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Any additional, properly filed, and
complete applications for a license in
the field of use filed in response to this
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
54987
notice will be treated as objections to
the grant of the contemplated exclusive
evaluation option license. Comments
and objections submitted to this notice
will not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: September 9, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–21855 Filed 9–12–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
SUMMARY:
A Novel Fusion Protein for Inhibiting
HIV Budding
Description of Technology: Ubiquitin
plays a critical role in HIV–1 budding.
Vectors containing deubiquitin enzymes
(DUbs) were constructed to deliver
DUbs to HIV–1 production sites in
living cells. The DUbs vectors comprise
DUb cDNAs and cDNA expressing
either HIV–1 gag, or the ESCRT protein
TSG101.
E:\FR\FM\15SEN1.SGM
15SEN1
]]>Agencies
[Federal Register Volume 79, Number 178 (Monday, September 15, 2014)]
[Notices]
[Page 54987]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-21855]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Evaluation License: Development of
Antibody-Drug Conjugates Comprising Topoisomerase Inhibitors for the
Treatment of Human Cancers
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive license
to practice the inventions embodied in U.S. Provisional Patent
Application No. 60/844,027 entitled, ``Azonafide derived tumor and
cancer targeting compounds,'' filed September 12, 2006 [HHS Ref. No. E-
160-2006/0-US-01], PCT Application No. PCT/US2007/078233 entitled,
``Azonafide derived tumor and cancer targeting compounds,'' filed
September 12, 2007 [HHS Ref. No. E-160-2006/0-PCT-02], European Patent
Application No. 7842310.0 entitled, ``Azonafide derived tumor and
cancer targeting compounds,'' filed September 12, 2007 [HHS Ref. No. E-
160-2006/0-EP-03], and U.S. Patent Application No. 12/441,029 entitled,
``Azonafide derived tumor and cancer targeting compounds,'' filed March
12, 2009 now US Patent No. 8,008,316 issued August 30, 2011 [HHS Ref.
No. E-160-2006/0-US-04], and all related continuing and foreign
patents/patent applications for the technology family, to Oncolinx,
Inc. The patent rights in these inventions have been assigned to the
Government of the United States of America.
The prospective exclusive evaluation option license territory may
be worldwide and the field of use may be limited to the development and
use of the licensed patent rights as a component of an antibody-drug
conjugate for the treatment of human cancers. Upon expiration or
termination of the exclusive evaluation option license, Oncolinx will
have the right to execute an exclusive patent commercialization license
which will supersede and replace the exclusive evaluation option
license with no broader territory than granted in the exclusive
evaluation option license and the field of use will be commensurate
with the commercial development plan at the time of conversion.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
September 30, 2014 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
comments, and other materials relating to the contemplated exclusive
evaluation option license should be directed to: Jennifer Wong, M.S.,
Senior Licensing and Patenting Manager, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Telephone: (301) 435-4633; Facsimile: (301)
402-0220; Email: wongje@od.nih.gov.
SUPPLEMENTARY INFORMATION: The present technology provides compound
formulation and method of use of improved derivatives of 2-[2'-(2-
aminoethyl)-2-methyl-ethyl]-l,2-dihydro-6-methoxy-3H-dibenz-
[de,h]isoquinoline-l,3-dione (herein referred to as azonafides),
anthracene-based DNA intercalcators that inhibit tumor growth. The
synthesized azonafides can be attached to a ligand or antibody to
recognize specific receptors on cancer cells and delivered as a
targeted cytotoxic payload. The azonafides have been developed to allow
for easy modification with different peptide linkers and antibodies,
but also allow for rapid release once cleaved in lysosomes after
delivery to the cancer cell enabling highly targeted attack of cancer
cells. The azonafides have reduced toxicity and lower development of
drug resistance.
The prospective exclusive evaluation option license is being
considered under the small business initiative launched on October 1,
2011 and will comply with the terms and conditions of 35 U.S.C. 209 and
37 CFR part 404. The prospective exclusive evaluation option license,
and a subsequent exclusive patent commercialization license, may be
granted unless within fifteen (15) days from the date of this published
notice, the NIH receives written evidence and argument that establishes
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
Any additional, properly filed, and complete applications for a
license in the field of use filed in response to this notice will be
treated as objections to the grant of the contemplated exclusive
evaluation option license. Comments and objections submitted to this
notice will not be made available for public inspection and, to the
extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 9, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-21855 Filed 9-12-14; 8:45 am]
BILLING CODE 4140-01-P
